Lipoprotein(a) is an LDL-like particle with an extra protein tail that makes it stickier and more inflammatory. Your level is set almost entirely by your genes, stays stable through life, and about one in five people inherits enough of it to matter.
Standard range versus optimal range
| Framework | Lp(a) value | Source |
|---|---|---|
| Rule out threshold | below 30 mg/dL | 2022 EAS consensus statement |
| Grey zone | 30-50 mg/dL | 2022 EAS consensus statement |
| Risk raising | 50 mg/dL and above, roughly 125 nmol/L | 2022 EAS consensus statement |
When it runs high
A high Lp(a) means inherited extra risk for heart attack, stroke and aortic valve narrowing that is independent of LDL cholesterol. The particle promotes plaque formation, carries oxidized phospholipids and interferes with clot breakdown, a combination no other lipoprotein shares.
- Inherited LPA gene variants, which explain over ninety percent of the level
- Chronic kidney disease, which can raise it modestly
- Menopause, which nudges it upward
- Hypothyroidism in some patients
When it runs low
Low Lp(a) is favorable and needs no action. Most of the worlds population falls into this group, and very low values carry no known harm.
- Inherited low-production gene variants, the common and benign explanation
The cholesterol risk your doctor may never have measured
Lp(a) was discovered in 1963 yet remains absent from most routine panels. That is unfortunate, because genetic studies show it causes heart disease directly, and elevated levels are among the most common inherited lipid risks. Roughly twenty percent of people carry a level above 50 mg/dL, and their lifetime risk of a cardiovascular event climbs by a third to a half compared with low carriers.
Why one lifetime measurement is usually enough
Diet, exercise and standard statins barely move Lp(a), because production is driven by gene variants that control the size of the apo(a) tail. The 2022 European Atherosclerosis Society consensus therefore recommends that every adult be measured at least once. A single result reframes risk permanently, and knowing it early justifies tighter control of every factor that can be changed, especially LDL and blood pressure.
What to do with a high result
While drugs that specifically silence Lp(a) production move through late stage trials, management today focuses on aggressive control of the modifiable risks. Guidelines suggest driving LDL lower than usual, treating blood pressure and glucose carefully, and checking heart valve health periodically. First degree relatives share half your genes, so a high result is worth a family conversation.